组胺 H 1受体 (H 1 R) 最近与介导细胞增殖和癌症进展有关;因此,高亲和力 H 1 R 选择性荧光配体是进一步研究这种体外和体内行为的理想工具。我们之前报道了一种基于拮抗剂 VUF13816 的带有肽接头的H 1 R 荧光配体,并试图进一步探索接头、正构和荧光部分周围的构效关系 (SAR)。在这里,我们报告了一系列高亲和力 H 1R 荧光配体的肽接头组成、正构靶向部分和荧光团各不相同。掺入基于硼-二吡咯甲烯 (BODIPY) 630/650 的荧光团赋予我们的 H 1 R 荧光配体高结合亲和力,显着压倒了在相应未标记同类物中观察到的接头 SAR。化合物31a既有效又具有亚型选择性,可在 10 nM 的浓度下使用共聚焦显微镜实现 H 1 R 可视化。31a与人类 H 1 R的分子对接预测优化的肽接头与受体中的关键残基相互作用。
组胺 H 1受体 (H 1 R) 最近与介导细胞增殖和癌症进展有关;因此,高亲和力 H 1 R 选择性荧光配体是进一步研究这种体外和体内行为的理想工具。我们之前报道了一种基于拮抗剂 VUF13816 的带有肽接头的H 1 R 荧光配体,并试图进一步探索接头、正构和荧光部分周围的构效关系 (SAR)。在这里,我们报告了一系列高亲和力 H 1R 荧光配体的肽接头组成、正构靶向部分和荧光团各不相同。掺入基于硼-二吡咯甲烯 (BODIPY) 630/650 的荧光团赋予我们的 H 1 R 荧光配体高结合亲和力,显着压倒了在相应未标记同类物中观察到的接头 SAR。化合物31a既有效又具有亚型选择性,可在 10 nM 的浓度下使用共聚焦显微镜实现 H 1 R 可视化。31a与人类 H 1 R的分子对接预测优化的肽接头与受体中的关键残基相互作用。
ylides derived from short-chain trialkylphosphines in the Wittig-type olefinationreactions toward the synthesis of alkenes, including stilbenes, styrenes, and 1,3-dienes, as well as reagents for homologation reactions, are described. The methods allow easy access to alkenes with high (E)-stereoselectivity in good yield. These reactions are conducted with weak bases in aqueous media, which allows easy
Microwave-Assisted, Aqueous Wittig Reactions: Organic-Solvent- and Protecting-Group-Free Chemoselective Synthesis of Functionalized Alkenes
作者:James McNulty、Priyabrata Das、David McLeod
DOI:10.1002/chem.201000438
日期:——
Free from protection! A general, chemoselective, protecting‐group‐ and organic‐solvent‐free route to stilbenes and heterostilbenes involving the direct synthesis of triethyl benzylic and allylic phosphonium salts from the corresponding alcohols and their microwave‐assisted, aqueous Wittig reactions is described.
The present invention generally relates to various compounds that are useful as α-synuclein ligands. The invention further relates to methods of using these compounds and their radiolabeled analogs for the detection of synucleinopathies, including Parkinson's disease (PD).
The present invention generally relates to various compounds that are useful as α-synuclein ligands. The invention further relates to methods of using these compounds and their radiolabeled analogs for the detection of synucleinopathies, including Parkinson's disease (PD).